Daunoxome

Do not use daunorubicin liposomal without first talking to your doctor if you have

• kidney disease;

• liver disease;

• heart disease;

• poor bone marrow function;

• received radiation therapy that encompassed the heart; or

• previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone).

The use of daunorubicin liposomal may be dangerous if you have any of the conditions listed above.

Daunorubicin liposomal is in the FDA pregnancy category D. This means that daunorubicin liposomal is known to be harmful to an unborn baby.Do not use daunorubicin liposomal without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with daunorubicin liposomal if necessary.

Daunorubicin liposomal passes into breast milk and may harm a nursing baby. Breast-feeding should be avoided during treatment with daunorubicin liposomal.

Daunorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Your doctor will determine the correct amount and frequency of treatment with daunorubicin liposomal depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.

Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with daunorubicin liposomal to monitor progress and side effects.

Skin accidentally exposed to daunorubicin liposomal should be rinsed thoroughly with soap and warm water.

Your healthcare provider will store daunorubicin liposomal as directed by the manufacturer. If you are storing daunorubicin liposomal at home, follow the directions provided by your healthcare provider.

Contact your doctor if you miss a dose of daunorubicin liposomal.

If you experience any of the following serious side effects from daunorubicin liposomal, contact your doctor immediately:

• an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);

• decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);

• congestive heart failure (difficulty breathing, fluid retention, chest pain);

• tissue or vein reactions near the site of administration;

• liver damage (abdominal pain, yellowing of the skin or eyes);

• nausea, vomiting, diarrhea, or loss of appetite;

• inflamation or sores inside the mouth, throat, or intestines;

• numbness or tingling;

• fever, chills, or other signs of infection; or

• back pain, flushing, and chest tightness while daunorubicin liposomal is being administered.

Other, less serious side effects may be more likely to occur. Continue taking daunorubicin liposomal and talk to your doctor if you experience:

• temporary hair loss; or

• red colored urine for 1 or 2 days following a dose.

Other side effects have also been reported. Discuss with your doctor any side effect that occurs during treatment with daunorubicin liposomal.

Daunorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Serious side effects have been reported with the use of daunorubicin liposomal including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with daunorubicin liposomal.

Daunorubicin liposomal can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with daunorubicin liposomal. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.

Skin accidentally exposed to daunorubicin liposomal should be rinsed thoroughly with soap and warm water.

Do not use daunorubicin liposomal without first talking to your doctor if you have had previous treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone). Because there is a maximum amount of these medications that should be administered to an individual, you may not be able to use daunorubicin liposomal.

Do not receive "live” vaccines during treatment with daunorubicin liposomal. Administration of a live vaccine may be dangerous during treatment with daunorubicin liposomal.

Drugs other than those listed here may also interact with daunorubicin liposomal. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with daunorubicin liposomal.

If for any reason an overdose of daunorubicin liposomal is suspected, seek emergency medical attention or contact your healthcare provider immediately.

Symptoms of a daunorubicin liposomal overdose tend to be similar to side effects caused by the medication, although often more severe.